<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bras Nefrol</journal-id><journal-id journal-id-type="iso-abbrev">J Bras Nefrol</journal-id><journal-id journal-id-type="publisher-id">jbn</journal-id><journal-title-group><journal-title>Jornal Brasileiro de Nefrologia</journal-title></journal-title-group><issn pub-type="ppub">0101-2800</issn><issn pub-type="epub">2175-8239</issn><publisher><publisher-name>Sociedade Brasileira de Nefrologia</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">37497829</article-id><article-id pub-id-type="pmc">PMC10726659</article-id><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2023-0077en</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis</article-title><trans-title-group xml:lang="pt"><trans-title>Inibidores da mTOR s&#x000e3;o a primeira escolha no tratamento de angiomiolipomas renais associados &#x000e0; esclerose tuberosa</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7256-6674</contrib-id><name><surname>Monich</surname><given-names>Aline Grosskopf</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role>contributed substantially to the design of the article</role><role>collection, analysis or interpretation of data</role><role>writing of the article and its critical review</role><role>final approval of the manuscript to be published</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8901-5553</contrib-id><name><surname>da Cunha</surname><given-names>Mariana Faucz Munhoz</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role>contributed substantially to the design of the article</role><role>collection, analysis or interpretation of data</role><role>writing of the article and its critical review</role><role>final approval of the manuscript to be published</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6394-9227</contrib-id><name><surname>Barreto</surname><given-names>Fellype Carvalho</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role>contributed substantially to the design of the article</role><role>collection, analysis or interpretation of data</role><role>writing of the article and its critical review</role><role>final approval of the manuscript to be published</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Universidade Federal do Paran&#x000e1;, Departamento de Cl&#x000ed;nica M&#x000e9;dica, Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Medicina Interna e Ci&#x000ea;ncias da Sa&#x000fa;de, Curitiba, PR, Brazil.</aff><aff id="aff2">
<label>2</label>Hospital Universit&#x000e1;rio Evang&#x000e9;lico Mackenzie, Servi&#x000e7;o de Nefrologia, Curitiba, PR, Brazil.</aff><aff id="aff3">
<label>3</label>Universidade Federal do Paran&#x000e1;, Departamento de Pediatria, Servi&#x000e7;o de Nefrologia Pedi&#x000e1;trica, Curitiba, PR, Brazil.</aff><aff id="aff4">
<label>4</label>Hospital Pequeno Pr&#x000ed;ncipe, Servi&#x000e7;o de Nefrologia Pedi&#x000e1;trica, Curitiba, PR, Brazil.</aff><aff id="aff5">
<label>5</label>Universidade Federal do Paran&#x000e1;, Departamento de Cl&#x000ed;nica M&#x000e9;dica, Servi&#x000e7;o de Nefrologia, Curitiba, PR, Brazil.</aff><author-notes><corresp id="c001">
<bold>Corresponding author:</bold> Fellype Carvalho Barreto. E-mail: <email>fellype.barreto@ufpr.br</email>
</corresp><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold> The authors have no conflict of interest related to this publication.</p></fn><fn fn-type="con"><p>
<bold>Authors&#x02019; Contribution</bold>
</p><p>AGM, MFMC and FCB contributed substantially to the design of the article; collection, analysis or interpretation of data; writing of the article and its critical review; and final approval of the manuscript to be published.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2023</year></pub-date><volume>45</volume><issue>4</issue><fpage>503</fpage><lpage>505</lpage><history><date date-type="received"><day>02</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2023</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><counts><table-count count="2"/><ref-count count="5"/></counts></article-meta></front><body><sec><title>Dear Editor</title><p>We read with great interest the case report &#x0201c;Endovascular treatment of intrarenal aneurysm bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease&#x0201d; by Leite et al.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>, in which embolization was successfully employed. In cases of bleeding, this preemptive interventional and curative treatment is preferable to partial or total nephrectomy, since it preserves the renal parenchyma and kidney function<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>. Currently, however, the preemptive treatment of choice for tuberous sclerosis-related angiomyolipomas is mTOR inhibitors, not embolization<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>
</sup>.</p><p>Tuberous sclerosis is an autosomal dominant disease caused by pathogenic variants of the <italic>TSC1</italic> and <italic>TSC2</italic> genes, which encode hamartin and tuberin proteins, respectively. Loss of function of these proteins causes aberrant activation of the mTOR pathway and, consequently, cell cycle modification, changes in the synthesis of proteins, growth factors and lipids, ultimately leading to exacerbated cell proliferation and tumor development and growth<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. mTOR inhibitors are deemed the first-choice therapy for several manifestations of tuberous sclerosis, including growing renal angiomyolipomas with more than 3 cm in diameter<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. From a renal standpoint, their potential benefits are: reduction in angiomyolipoma size, lower risk of bleeding due to reduction of intratumoral aneurysms, less need for surgical interventions and preservation of kidney function<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>
</sup>. Cohort studies have also reported a shift in the preventive treatment of renal angiomyolipomas from embolization to mTOR inhibitors<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>.</p><p>In agreement with previous studies,<sup>
<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>
</sup> preliminary data from an observational cohort study including patients with tuberous sclerosis followed at the Nephrology Service of the Clinics Hospital of the Federal University of Paran&#x000e1; (author&#x02019;s data) have shown a higher prevalence of angiomyolipomas, renal complications, need of surgical interventions, and of chronic kidney disease in adults compared to pediatric patients. Importantly, our data indicate that a change in the health care provided to these patients is urgently required. The most frequent surgical interventions were still partial and total nephrectomies. Furthermore, despite the clear indications favoring the prescription of an mTOR inhibitor, only a small portion of patients were in use of this medication prior to the first consultation with a nephrologist (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1.</label><caption><title>Clinical characteristics of kidney involvement in patients with tuberous sclerosis</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Pediatric patients (&#x0003c;18 years)</th><th align="center" valign="top" rowspan="1" colspan="1">Adult patients (&#x02265;18 years)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Patients, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">23 (48.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (51.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">9 &#x000b1; 4</td><td align="center" valign="top" rowspan="1" colspan="1">25 &#x000b1; 7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Males, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">13 (56.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (54.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Renal angiomyolipomas, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">6 (26%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (75%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilateral involvement (%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (94.4%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Kidney cysts, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">7 (30.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (29.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Stage of CKD</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD G2, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD G3a, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3 (12.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD G3b, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD G4, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD G5, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RRT, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>SH, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (16.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Use of mTOR inhibitors, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">7 (30.4%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (25%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neurological indication, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">4 (57.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (33.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiac indication, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (14.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (16.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Renal indication, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">3 (50%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dermatologic involvement, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (28.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>History of kidney complications, <italic>n (%)</italic>
</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retroperitoneal hemorrhage, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2 (28.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Partial nephrectomy, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (14.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total nephrectomy, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2 (28.5%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arterial embolization, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (14.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death by hemorrhagic shock, <italic>n (%)</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (14.3%)</td></tr></tbody></table><table-wrap-foot><fn><p>CKD: chronic kidney disease; SH: systemic hypertension; RRT: renal replacement therapy.</p></fn></table-wrap-foot></table-wrap><p>The case report by Leite et al. highlights that less invasive, renal-sparing surgery provides effective therapy for patients with bleeding from renal AML, one of the most feared complications of tuberous sclerosis, which can result in hemorrhagic shock and death<sup>
<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Additionally, we would like to emphasize that tuberous sclerosis patients need regular medical follow-up over lifetime. They must be followed up regularly sincd childhood by a nephrologist, in order to enable early diagnosis of renal involvement, monitoring of its progression and of kidney function, which may allow starting timely mTOR inhibitor treatment, in order to decrease the risk of renal complications and the need for surgery. A multidisciplinary approach, together with strengthening the knowledge about tuberous sclerosis among health care professionals, is crucial for improving the quality of life and survival of these patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the multidisciplinary team of the Pediatric Neurology Center of the Clinics Hospital of the Federal University of Paran&#x000e1; (CENEP &#x02013; CHC/UFPR) for their involvement in the care of patients with tuberous sclerosis.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leite</surname><given-names>T</given-names></name>
<name><surname>Pazinato</surname><given-names>LV</given-names></name>
<name><surname>Vidal</surname><given-names>MJA</given-names></name>
<name><surname>Freitas</surname><given-names>D</given-names></name>
<name><surname>Leal Fo</surname><given-names>JMM.</given-names></name>
</person-group><article-title>Endovascular treatment of intrarenal aneurysms bleeding and angiomyolipomas in a patient with tuberous sclerosis and polycystic kidney disease.</article-title><source>J Bras Nefrol.</source><year>2023</year><volume>45</volume><issue>1</issue><fpage>111</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1590/2175-8239-jbn-2021-0023</pub-id><pub-id pub-id-type="pmid">34328493</pub-id>
</element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>JM</given-names></name>
<name><surname>Racadio</surname><given-names>JM</given-names></name>
<name><surname>Johnson</surname><given-names>ND</given-names></name>
<name><surname>Donnelly</surname><given-names>LF</given-names></name>
<name><surname>Bissler</surname><given-names>JJ.</given-names></name>
</person-group><article-title>Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex.</article-title><source>Am J Kidney Dis.</source><year>2006</year><volume>47</volume><issue>1</issue><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.09.028</pub-id><pub-id pub-id-type="pmid">16377390</pub-id>
</element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bissler</surname><given-names>JJ</given-names></name>
<name><surname>Christopher Kingswood</surname><given-names>J.</given-names></name>
</person-group><article-title>Renal manifestation of tuberous sclerosis complex.</article-title><source>Am J Med Genet C Semin Med Genet.</source><year>2018</year><volume>178</volume><issue>3</issue><fpage>338</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1002/ajmg.c.31654</pub-id><pub-id pub-id-type="pmid">30307110</pub-id>
</element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Zhou</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Yang</surname><given-names>T</given-names></name>
<name><surname>Zhou</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.</article-title><source>Orphanet J Rare Dis.</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13023-019-1012-x</pub-id><pub-id pub-id-type="pmid">30760308</pub-id>
</element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kingswood</surname><given-names>JC</given-names></name>
<name><surname>Belousova</surname><given-names>E</given-names></name>
<name><surname>Benedik</surname><given-names>MP</given-names></name>
<name><surname>Carter</surname><given-names>T</given-names></name>
<name><surname>Cottin</surname><given-names>V</given-names></name>
<name><surname>Curatolo</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal Angiomyolipomas.</article-title><source>Front Neurol.</source><year>2020</year><volume>11</volume><fpage>972</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00972</pub-id><pub-id pub-id-type="pmid">33041968</pub-id>
</element-citation></ref></ref-list></back></article>
